Nationwide Fund Advisors boosted its position in shares of Sage Therapeutics Inc. (NASDAQ:SAGE) by 5.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,650 shares of the biopharmaceutical company’s stock after buying an additional 1,650 shares during the period. Nationwide Fund Advisors owned 0.10% of Sage Therapeutics worth $1,411,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. BlackRock Fund Advisors raised its position in shares of Sage Therapeutics by 17.1% in the first quarter. BlackRock Fund Advisors now owns 787,546 shares of the biopharmaceutical company’s stock worth $25,249,000 after buying an additional 115,027 shares during the last quarter. Hamilton Lane Advisors LLC bought a new stake in shares of Sage Therapeutics during the second quarter worth about $329,000. Eagle Asset Management Inc. increased its stake in shares of Sage Therapeutics by 3.2% in the second quarter. Eagle Asset Management Inc. now owns 873,924 shares of the biopharmaceutical company’s stock worth $26,331,000 after buying an additional 27,319 shares during the period. RS Investment Management Co. LLC increased its stake in shares of Sage Therapeutics by 1.8% in the second quarter. RS Investment Management Co. LLC now owns 586,826 shares of the biopharmaceutical company’s stock worth $17,681,000 after buying an additional 10,435 shares during the period. Finally, Candriam Luxembourg S.C.A. increased its stake in shares of Sage Therapeutics by 7.2% in the second quarter. Candriam Luxembourg S.C.A. now owns 74,000 shares of the biopharmaceutical company’s stock worth $2,230,000 after buying an additional 5,000 shares during the period.

Institutional Ownership by Quarter for Sage Therapeutics (NASDAQ:SAGE)

Sage Therapeutics Inc. (NASDAQ:SAGE) traded up 0.87% during trading on Tuesday, reaching $50.80. The company’s stock had a trading volume of 381,136 shares. Sage Therapeutics Inc. has a 1-year low of $26.28 and a 1-year high of $62.64. The company’s 50-day moving average is $45.92 and its 200-day moving average is $39.77. The company’s market capitalization is $1.89 billion.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported ($1.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.10) by $0.05. Equities analysts anticipate that Sage Therapeutics Inc. will post ($4.35) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This report was posted by Financial Market News and is the sole property of of Financial Market News. If you are accessing this report on another website, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at http://www.financial-market-news.com/nationwide-fund-advisors-raises-position-in-sage-therapeutics-inc-sage/1209454/.

A number of analysts have issued reports on SAGE shares. Raymond James Financial Inc. started coverage on Sage Therapeutics in a research note on Tuesday, September 13th. They issued an “outperform” rating and a $75.00 target price for the company. Cowen and Company reaffirmed a “buy” rating on shares of Sage Therapeutics in a research note on Monday, September 19th. Canaccord Genuity set a $110.00 target price on Sage Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, September 6th. Leerink Swann reaffirmed an “outperform” rating and issued a $68.00 target price on shares of Sage Therapeutics in a research note on Tuesday, October 4th. Finally, Zacks Investment Research raised Sage Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 26th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $69.54.

In other news, CFO Kimi Iguchi sold 1,500 shares of the company’s stock in a transaction on Friday, November 11th. The stock was sold at an average price of $50.59, for a total value of $75,885.00. Following the sale, the chief financial officer now directly owns 79,739 shares in the company, valued at $4,033,996.01. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.60% of the stock is owned by insiders.

Sage Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. Its lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor.

5 Day Chart for NASDAQ:SAGE

Want to see what other hedge funds are holding SAGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sage Therapeutics Inc. (NASDAQ:SAGE).

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.